Seeking Alpha
14 Aug 2026, 04:43 UTC · 1h ago
Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
14 Aug 2026, 04:43 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Alamar Biosciences reported Q2 2026 revenue growth of 82% year-over-year to $29.4 million. — Strong top-line growth indicates rapid market adoption of the company's proteomics platform.
+0.60Consumables sales grew 147% year-over-year, with gross margins increasing to 60%. — High-growth, high-margin recurring revenue significantly improves the long-term valuation and profitability profile.
+0.50The company is utilizing its existing instrument installed base to deploy new assays, creating workflow stickiness. — Capital-efficient expansion reduces the cost of customer acquisition and increases switching costs for users.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The author is bullish due to 82% YoY revenue growth, rising gross margins, and strong consumables sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
40m ago
